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Available online 23 October 2016Autophagy is a catabolic process that facilitates nutrient recycling via degradation of damaged organelles and
proteins through lysosomal mediated degradation. Alterations in this complex, and tightly regulated process,
lead to disease. Autophagy iswidely accepted as cytoprotective against neurodegenerative diseases and a variety
of clinical interventions are moving forward to increase autophagy as a therapeutic intervention. Autophagy has
both positive and negative roles in cancer and this has led to controversy overwhether or howautophagymanip-
ulation should be attempted in cancer therapy. Nevertheless, cancer is the disease wheremost current activity in
trying to manipulate autophagy for therapy is taking place and dozens of clinical trials are using autophagy inhi-
bition with Chloroquine or Hydroxychloroquine in combination with other drugs for the treatment of multiple
neoplasms. Here, we review recent literature implicating autophagy in neurodegenerative diseases and cancer
and highlight some of the opportunities, controversies and potential pitfalls of therapeutically targeting
autophagy.
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The award of the 2016 Nobel Prize forMedicine or Physiology to Pro-
fessor Yoshinori Ohsumi for his work on elucidating mechanisms of au-
tophagy recognizes the importance of autophagy for human disease.
Autophagy allows cells to maintain intracellular homeostasis and re-
spond to stress by degrading proteins, organelles and other cellular com-
ponents via the lysosome. This process is evolutionally conserved andis review were obtained from
ncer”, “Huntington's disease”,
trial information was obtained
tophagy”, “chloroquine”, and
lish from 1993 to 2016 were
o 2016.
horburn).
. This is an open access article underacts as a critical cellular response to nutrient and oxygen deprivation,
resulting in recycled amino acids, nutrients, and lipids. Alterations in au-
tophagy and inherited mutations in autophagy related genes, known as
ATG genes, that control autophagy have been linked to human disease,
including neurological diseases, autoimmune disease, metabolic disor-
ders, infectious disease and cancer. These connections imply that thera-
peutic interventions to boost or inhibit autophagy may be useful to
treat or prevent disease (Rubinsztein et al., 2012). Here we review the
roles of autophagy in two such diseases– neurodegenerative disease
and cancer– where direct therapeutic targeting intended to stimulate
and inhibit autophagy is moving forward in the clinic.
2. Opportunities to Target Autophagy for Therapy
Three types of autophagy have been characterized– microautophagy,
chaperone mediated autophagy (CMA), and macroautophagy.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of cytosolic material, (Li et al., 2012) while CMA is facilitated by chaper-
ones that target proteins containing a speciﬁc amino acid motif to the ly-
sosome. AlthoughCMA is implicated indisease (Cuervo andWong, 2014),
this review will focus on macroautophagy.
Macroautophagy (from here on termed autophagy) is characterized
by the formation of double membrane vesicles called autophagosomes
that engulf cytoplasmicmaterial then fusewith the lysosome to degrade
their contents. The process involves various steps: initiation, nucleation,
elongation, and closure of the membranes that form the
autophagosome, fusion with the lysosome and recycling of macromo-
lecular precursors. Each step is regulated by particular autophagy-relat-
ed proteins (ATGs) (Mizushima et al., 2011). Autophagy is controlled
transcriptionally by MITF and FOXO families of transcription factors
(Füllgrabe et al., 2014), as well as CREB and ATF (Amaravadi, 2015)
and is subject to post-translational regulation allowing its pharmacolog-
ical manipulation both positively and negatively (Fig. 1). For example,
themammalian target of rapamycin (mTOR) complex,mTORC1 inhibits
autophagy. Thus, mTOR inhibitors are often used to stimulate autopha-
gy. mTORC2 has also been linked to autophagy, although this may be
speciﬁc to CMA (Arias et al., 2015). Autophagy can also be induced inde-
pendently of mTOR. For example, the naturally occurring disaccharide,
trehalose, which works independently of mTOR (Sarkar et al., 2007a),
induces autophagy to protect against liver disease by affecting glucose
transporters (DeBosch et al., 2016).
Other interventions inhibit autophagy, including inhibitors of the
protein kinases, ULK1 and ULK2 (Egan et al., 2015, Petherick et al.,
2015), and the class III phosphoinositide-3-kinase, (VPS34) (Bago et
al., 2014; Dowdle et al., 2014; Ronan et al., 2014). VPS34 is a componentFig. 1. Interventions that target autophagy. Macroautophagy is controlled by nutrient availabilit
formation of Ulk1/2 complexes. Ulk complexes facilitate Beclin-1 complex formation and phagap
12 conjugation. Finally, double membrane autophagasomes fuse with lysosomes to form au
hydrolases. A number of pharmacological and naturally occurring agents have been designe
regulate autophagy.of the BCL-2 interactingmoesin-like coiled-coil protein 1, (Beclin-1) sig-
naling complex. Beclin-1 contains a BH3 domain, allowing it to interact
with other BH3 containing proteins, including B cell CLL/lymphoma 2
(BCL-2), and the downstream functions of the Beclin-1 complex can dif-
fer with respect to autophagy, dependent on the molecules found in
complex with it (Sinha and Levine, 2008). Other components of the
complex include ultraviolet irradiation resistant-associated gene
(UVRAG), SH3GLB2, (also known as BIF-1), and activating molecule in
Beclin-1 regulated autophagy 1 (AMBRA1). Some of these interactions
can be pharmacologically targeted. BH3 mimetics like Venetoclax,
which was designed to induce apoptosis by blocking BCL-2 interactions
at the mitochondria, also disrupt interactions between Beclin-1 and
BCL-2 to induce autophagy (Maiuri et al., 2007). However, this mecha-
nism has been challenged and it has been proposed that BH3 mimetics
may only affect autophagy via indirect mechanisms that occur some-
time after they have hit their direct target (Reljic et al., 2016). A cell-per-
meable peptide, Tat-Beclin1, disrupts another interaction in the Beclin-1
complex to induce autophagy (Shoji-Kawata et al., 2013). In addition to
themany drugs that canmodulate autophagy (Levine et al., 2015), non-
pharmacological interventions including caloric restriction and exercise
also induce autophagy. For example, exercise targets the Beclin-1 sig-
naling complex to induce autophagy that can protect mice against dia-
betes (He et al., 2012). Two ubiquitin-like conjugation systems
elongate the autophagosome membrane. The ubiquitin-like protein
ATG12 is conjugated to ATG5 in a process requiring the E1-like enzyme,
ATG7. A similar lipid conjugation system (also using ATG7) attaches
phosphatidylethanolamine (PE) to the Microtubule Associated Protein
1 light chain 3 (MAP1LC3) andGABA type A receptor-associated protein
(GABARAP) families of proteins. Pharmacological inhibitors of ATG7y via regulation bymTORC1, which under conditions of nutrient availability can inhibit the
hore initiation. Phagaphore elongation is thenmediated by LC3-PE conjugation andATG5-
tophagolysosomes resulting in degradation of autophagosome contents by lysosomal
d/discovered that target this pathway allowing interventions that upregulate and down
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jugation occurs after cleavage and processing of LC3 by the protease,
ATG4B, which can also be inhibited pharmacologically (Akin et al.,
2014). LC3-PE is incorporated into the autophagosome membrane and
is the most common marker of autophagy (Klionsky et al., 2016). The
ﬁnal step is to fuse the autophagosome with the lysosome by the
SNARE protein, STX17 (Itakura et al., 2012). This step can be blocked
with lysosomal inhibitors such as chloroquine (CQ) and
hydroxychloroquine (HCQ) or Baﬁlomycin A1. Once fusion is complete,
the lysosomal hydrolases degrade the contents of the autophagosomes
producing amino acids, nutrients, and lipids that are available to fuel
protein and other macromolecular synthesis and metabolism.
3. Targeting Autophagy in Neurological Diseases
Autophagy has been implicated in neurodegenerative disease for
two reasons. First, defects in autophagy cause neurodegeneration. For
example, although systemic knockout of Atg7 leads to neonatal death
inmice (Komatsu et al., 2005), neuronal deletion allows themice to sur-
vive to adulthood, however the animals succumb to neurodegenerative
disease (Komatsu et al., 2006). Moreover, when Atg7 is acutely deleted
in all cells in adult animals, the most common cause of death is neuro-
degenerative diseasewith accumulation of ubiquitinated protein aggre-
gates (Karsli-Uzunbas et al., 2014). Amutation in the human ATG5 gene
that inhibits autophagy also causes congenital ataxia and developmen-
tal delay (Kim et al., 2016). The second link to neurodegenerative dis-
eases including Alzheimers Disease (AD), Parkinson's Disease (PD),
and Huntington's Disease (HD) is the involvement of toxic protein ag-
gregates that can be degraded via autophagy in the pathology of all of
these diseases (Nah et al., 2015).
Alzheimer's disease is themost common progressive neurodegener-
ative dementia and is characterized by the accumulation of plaques and
intra-neuronal ﬁbrillary tangles, where the former consists of beta-am-
yloid peptides (Aβ) that are highly insoluble and toxic (Querfurth and
LaFerla, 2010), and the latter is composed of hyperphosphorylated mi-
crotubule-associated protein TAUaggregates (Wang et al., 2013). Defec-
tive lysosomal proteolysis and compromised autophagosome transportTable 1
Compounds that directly/indirectly upregulate autophagy in neurodegenerative diseases.
Disease Compound Mechanism Mod
Alzheimer's AVN-211 Antagonist of 5-HT6R (mTOR
activator)
Rod
Lu AE58054 (AKA
idalopirdine)
Antagonist of 5-HT6R (mTOR
activator)
Pha
SB-742457 Antagonist of 5-HT6R (mTOR
activator)
Pha
AUTEN-67 MTMR-14 (autophagy inhibitor) Dro
mod
rAAV/Aβ vaccine AKT/mTOR Rod
ACAT1 Unknown Neu
Rapamycin Antagonist to mTOR Rod
Nicotinamide Lysosomal acidiﬁcation Pha
Resveratrol Antagonist to TORC1 Pha
Lithium AMPK Pha
Latrepirdine Antagonist to mTOR Pha
Metformin Antagonist to mTOR/PP2A Pha
Parkinson's DMF Activation of NRF2 Rod
Curcumin TFEB Rod
BECN1 gene Beclin-1 complex Rod
TFEB gene TFEB regulation Rod
Huntington's AUTEN-67 MTMR-14 Dro
Rapamycin/CCI-779 Antagonist to mTOR Dro
Berberine Unknown Rod
Rheb gene Activator of mTOR Rod
Calpastatin Calpain inhibitor Rod
Rilmenidine Unknown Rod
Trehalose Unknown Rodoccurs in AD resulting in an accumulation of autophagosomes aswell as
Aβ peptides and Tau protein aggregates (Zhang et al., 2016).
Huntington's disease is an autosomal dominant disease caused by
CAG repeat expansion in the portion of the gene containing several glu-
tamines, known as the polyglutamine (Poly Q) tract of the HTT gene
(Novak and Tabrizi, 2010) and patients present with cognitive dysfunc-
tion and a loss of motor control thought to be due to toxic aggregates
from the polyQ containing protein. Cytoplasmic aggregates formed by
mutant forms of HTT (mHTT) can be removed by autophagy, and stim-
ulation of autophagy with mTOR inhibitors, as well as mTOR indepen-
dent autophagy inducers, can reduce neuronal toxicity in Huntington's
disease models (Sarkar et al., 2007b) (Table 1). Autophagosomes in
HD disease may also be defective and are often devoid of contents
resulting in abnormal amounts of mHTT protein aggregates that are
not degraded by the lysosome (Martinez-Vicente et al., 2010). Addition-
ally, mHTT itself affects autophagy resulting in accumulation of
autophagosomes that are unable to fuse with lysosomes (Wong and
Holzbaur, 2014).
Accumulation ofα-synuclein (SNCA) deﬁnes themolecular patholo-
gy of Parkinson's disease, a progressive disorder that results from the
death of dopaminergic neurons in the substantia nigra. Patients accu-
mulate Lewy bodies, intracytoplasmic inclusions containing SNCA,
which act as a neurotoxin. Macroautophagy, CMA, as well asmitophagy
(i.e. selective autophagy of mitochondria) have all been implicated in
PD (Nah et al., 2015; Narendra et al., 2008). Notably, Pink1 and Parkin,
two proteins whose loss of function is directly linked to Parkinson's dis-
ease, also help facilitate the removal of damaged mitochondria by the
process of mitophagy, and loss of this process resulting in an accumula-
tion of dysfunctional mitochondria has been shown to be causative for
the disease (Rub et al., 2016). Additionally, loss of autophagy results in
increased oxidative stress, which exacerbates PD pathology
(Surendran and Rajasankar, 2010).
In light of these and other studies suggesting that autophagy plays a
cytoprotective role against neurodegenerative diseases (Rubinsztein et
al., 2015), a number of interventions to enhance autophagic ﬂux, that
is the fusion of lysosomes and autophagosomes and degradation of
autophagosome cargo, have been tested (Table 1). One study showsel tested/clinical trial phase Reference
ent models (Ivachtchenko et al., 2016)
se III (Wilkinson et al., 2014)
se II (Maher-Edwards et al., 2010)
sophilia, Zebraﬁsh and preclinical rodent
el
(Papp et al., 2016)
ent models (Wang et al., 2015)
roblastoma cells and rodent models (Shibuya et al., 2015)
ent models (Caccamo et al., 2010, Siman et al.,
2015)
se I (Liu et al., 2013)
se III (Vingtdeux et al., 2010)
se II (Forlenza et al., 2012)
se III (Steele and Gandy, 2013)
se II (Kickstein et al., 2010)
ent models (Lastres-Becker et al., 2016)
ent models (Ji and Shen, 2014, Song et al., 2016)
ent model (Spencer et al., 2009)
ent model (Decressac et al., 2013)
sophila (Billes et al., 2016)
sophila and Rodent models (Ravikumar et al., 2004)
ent models (Jiang et al., 2015)
ent models (Lee et al., 2015)
ent models (Menzies et al., 2015)
ent models (Rose et al., 2010)
ent models (Sarkar and Rubinsztein, 2008)
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could reduce Aβ and hyperphosphorylated Tau as well as improve cog-
nitive performance, all dependent on restoration of autophagy (Liu et
al., 2013). Resveratrol inhibits rotenone-induced dopaminergic neuron
cell death in amodel of PD (Lin et al., 2014). Because the effectswere ab-
rogated by an autophagy inhibitor this is thought to be due to autopha-
gy. mTOR inhibitors such as rapamycin and CCI-779 can induce
autophagy to improve motor neuron functioning in ﬂy and mouse
models of HD (Ravikumar et al., 2004). Consequently, several com-
pounds including many that feed into mTOR signaling are moving for-
ward towards clinical trials for different diseases (Table 1). One such
class of drugs antagonize the G-protein coupled receptor, 5-HT6R,
known to activate mTOR signaling in the brain (Meffre et al., 2012),
and include the compounds AVN-211 (Ivachtchenko et al., 2016)
(Morozova et al., 2014) (Phase IIa clinical trial for Schizophrenia,
highlighting safety), Lu AE58054 (AKA idalopirdine)(Wilkinson et al.,
2014)(Phase III clinical trial for AD - NCT02006641, NCT02006654,
NCT02079246), and SB-742457(Maher-Edwards et al., 2010) (Phase II
clinical trial for AD- NCT00224497, NCT0034819, NCT00708552,
NCT00710684).
There are caveatswith the abovementioned studies. First, there is no
good method for accurately quantifying autophagy in vivo, and espe-
cially in human patients. This makes it difﬁcult to be sure that drugs
that increase autophagic ﬂux in cultured cells are also doing so in vivo.
Second, agents that activate autophagy also have other effects, for ex-
ample mTOR inhibitors also affect protein, nucleotide, and lipid synthe-
sis as well as glutamine metabolism and glycolysis all via autophagy
independent mechanisms (Li et al., 2014). This makes it difﬁcult to
know if the beneﬁcial effects are due to increased autophagy or other ef-
fects. An advantage in preclinical models is the ability to design con-
trolled experiments where an intervention intended to increase
autophagy is also tested in animals with a separate genetic interference
of autophagy, which should abrogate the protective effects seen by the
intervention. However, this kind of experiment is also subject to criti-
cism; it may show that autophagy is necessary for protection against
disease but doesn't necessarily mean that the increase in autophagy is
responsible. A major hurdle for the ﬁeld is to develop better ways to
stimulate autophagy in a more speciﬁc manner. In summary, while
more work is needed to fully elucidate the mechanisms of these com-
pounds and their therapeutic potential, upregulation of autophagy re-
mains a promising therapeutic approach for neurodegenerative
diseases such as Alzheimer's, Parkinson's and Huntington's disease.
4. Targeting Autophagy in Cancer
Most clinical studies that are attempting to therapeutically target au-
tophagy are in cancer. A recent search of ClinicalTrials.Gov using the
search term “autophagy” brought up over 60 clinical trials, of which
N50 are cancer trials attempting to inhibit autophagy. This is somewhat
surprising because, unlike with neurodegenerative diseases where the
consensus view is that autophagy protects against disease, autophagy
can both promote and inhibit tumor growth and autophagy's roles
vary in different context (White, 2015).
Autophagy was ﬁrst suggested to be a tumor suppressor when a
study from Beth Levine's group (Liang et al., 1999) found that Beclin-1
interacts with an oncogenic protein (BCL-2) and some breast, prostate,
and ovarian cancer tumors had a monoallelic loss in BECN1 (encoding
Beclin-1). In human tumors, these results are complicated by close
proximity of the BECN1 gene and the potent tumor suppressor BRCA1
(Laddha et al., 2014; Tang et al., 2015). This makes it difﬁcult to rule
out the possibility that in human tumors, it is loss of BRCA1 rather
than BECN1 that is important. Indeed, TCGA data shows there is no sig-
niﬁcant loss of BECN1 independent of BRCA1 loss (White, 2015). Inmice,
monoallelic deletion of the Becn1 gene alone is sufﬁcient to causemam-
mary hyperplasia, (Qu et al., 2007; Yue et al., 2003) with possible con-
text-speciﬁc effects with different oncogenic drivers (Cicchini et al.,2014). However, the Becn1+/− genotype still maintains functional au-
tophagy, while other autophagy knockouts that aremuchmore system-
ically deﬁcient in autophagy (Yoshii et al., 2016) do not develop cancer
suggesting that the Becn1+/− tumor phenotypemay be autophagy inde-
pendent. Mutation of other autophagy regulators (e.g. the UVRAG
(Liang et al., 2006), BIF1 (Coppola et al., 2008), and AMBRA proteins
(Cianfanelli et al., 2015)) that are all in the Beclin-1 complex have also
been implicated in cancer. However, all of these molecules and Beclin1
itself also have autophagy independent roles. These complications
mean that it is possible that some tumor suppressor effects of Beclin1
and other components of the complex are actually due to autophagy-in-
dependent functions.
In KRAS-driven mouse models, knockout of Atg5 or Atg7 often pro-
motes pre-malignant lesions (Rao et al., 2014; Rosenfeldt et al., 2013;
Yang et al., 2014,). KO of Atg5 delays the onset of lung cancer in KRAS-
driven model of lung cancer, although once tumors do progress, Atg5
loss enhances survival (Rao et al., 2014). Likewise, in a KRAS-driven
pancreatic cancermodel, loss ofAtg5orAtg7 accelerates tumor initiation
but blocksmalignant progression (Rosenfeldt et al., 2013). Although not
fully understood, both these studies also demonstrated a role for TP53 in
switching between pro and anti-tumorigenic roles of autophagy. A re-
cent study found that mutations in a splicing factor increased cell trans-
formation by incorrectly processing the ATG7 mRNA resulting in
decreased ATG7 protein and defective autophagy (Park et al., 2016),
again suggesting that autophagy protects against early steps in tumor
development. Taken together, these various studies suggest that au-
tophagy may play a role in suppressing tumor initiation but can pro-
mote tumor progression. Consistent with this idea, genetic
enhancement of autophagy (by overexpression of active TFEB, a master
transcriptional regulator of autophagy) can increase growth of
established tumors (Wei et al., 2014).
In vitro studies using shRNAs to target N100 autophagy regulators
identiﬁed a number of breast cancer cell lines that are dependent
upon functional autophagy for growth even in the absence of stress
(Maycotte et al., 2014). Importantly however, some tumor cell lines
were barely affected by autophagy gene knockdown indicating that
tumor cells differ greatly in their dependence on autophagy. This work
followed studies suggesting that cancer cell lines with mutant RAS
genes are “autophagy addicted” (Guo et al., 2011) and some tumor
types, e.g. pancreas cancer, which transcriptionally induces high levels
of autophagy (Perera et al., 2015), are highly dependent on autophagy
(Yang et al., 2011). However, RAS mutation alone does not determine
sensitivity to autophagy inhibition in vitro (Morgan et al., 2014)
highlighting the need for more rigorous studies to identify which
tumor cells are, or are not, autophagy-dependent.
Similarly, in vivo studies have indicated the necessity of Atg5 or Atg7
in KRAS- or BRAF-driven tumor models (Karsli-Uzunbas et al., 2014;
Rao et al., 2014; Rosenfeldt et al., 2013; Yang et al., 2014; Guo et al.,
2013; Strohecker et al., 2013; Xie et al., 2015). A requirement for au-
tophagy tomaintain tumors in vivo has also been demonstrated for can-
cers driven by PTEN loss (Santanam et al., 2016). Moreover, additional
autophagy regulators such as FIP200, have been shown to maintain
tumor growth due to autophagy and not other functions of the protein
(Chen et al., 2016). One caveat for many of themouse studies is that de-
letion of the Atg gene occurs simultaneouslywith activation of the onco-
genic driver and occurs only in the tumor cells. These experiments do
not adequately model what autophagy inhibition would be like in the
clinic. A patient would likely only be treated after they had a full-
blown cancer with an autophagy inhibitor that cannot discriminate be-
tween autophagy in the cancer cells and autophagy in the rest of the
body. This has beenmodeled in KRAS-driven lung cancer, where tumors
were allowed to develop before systemic loss of the Atg7 gene was
achieved (Karsli-Uzunbas et al., 2014). Complete, irreversible inhibition
of autophagy by Atg7 deletion in adult mice caused death by bacterial
infection or, after several weeks, neurodegeneration and the animals
displayed defects in glucose homeostasis and extreme sensitivity to
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where the tumor can be eradicated without wholesale toxicity when
autophagy is inhibited. The existence of such a therapeutic window– a
given dose and/or length of treatment time that can be effective in
inhibiting tumor growth without overt toxicity, provides an opportuni-
ty for therapeutic inhibition. In the clinic we would likely never have a
drug that is as good at inhibiting autophagy as complete knockout of
an ATG gene. Moreover, autophagy inhibition with a drug could be re-
versed by removing the drug, thus this work tells us that even a “per-
fect” autophagy inhibitor might not be so toxic that it couldn't be used
in cancer therapy.
As with its tumor suppressing roles, the mechanisms by which au-
tophagy supports tumor growth are poorly understood. Autophagy
has been implicated in the pro-tumorigenic processes of glycolysis, ox-
idative metabolism, cell proliferation and anchorage-independent
growth (Lock et al., 2011; Vander Heiden et al., 2009). In addition au-
tophagy is involved in metastasis (Keniﬁc et al., 2010). For example, it
is important in tumor cell invasion and migration, and metastasis in
vivo due to autophagy induced focal adhesion disassembly (Keniﬁc et
al., 2016; Shariﬁ et al., 2016) and autophagy-regulated cytokine secre-
tion (Lock et al., 2014). Autophagy deﬁciency in cancer cells results in
multiple metabolic problems and the accumulation of defective mito-
chondria (Guo et al., 2016). Additionally autophagy in stromal cells
can promote tumor cell metabolism by feeding amino acids (speciﬁcally
alanine) to the tumor cells (Sousa et al., 2016). It is likely that a combi-
nation of metabolic effects and other cellular functions such as cytokine
secretion contribute to autophagy's ability to promote tumor growth
and progression and thus explain how, for some tumors, autophagy in-
hibition alone can have profound anti-cancer effects.
Autophagy also plays a role in response to treatment. An extensive
literature suggests that autophagy can protect cancer cells againstTable 2
Active and recently completed clinical trials (last 2 years) with autophagy inhibition for the tre
Tumor type Clinical trial
phase
Drug combination
Breast Phase II CQ + Taxols (microtub
Breast Phase II CQ
Breast (DCIS*) Phase I/II CQ
Pancreatic Phase I CQ + gemcitabine
Pancreatic Phase I/II HCQ + gemcitabine
Pancreatic Phase II HCQ + gemcitabine (DN
Pancreatic Phase I/II HCQ + gemcitabine (DN
Melanoma Phase I CQ + radiation + DT01
Melanoma Phase I/II HCQ + Trametinib (ME
Small cell lung Phase I CQ
Small cell lung Phase I CQ + radiotherapy
Non-small cell lung Phase II HCQ + Paclitaxol (mycr
(angiogenesis inhibitor)
Colorectal Phase I/II HCQ + Oxaliplatin (alyl
inhibitor)
Colorectal Phase II HCQ + Bevacizumab (a
Colorectal Phase II HCQ + Vorinostat (HDA
Prostate Phase II HCQ + ABT-263 (Bcl in
Prostate Phase II HCQ
Renal cell carcinoma Phase I/II HCQ + RAD001 (mTOR
Glioblastoma, astrocytoma Phase II CQ + chemoradiation w
Glioma, chondrosarcoma, intrahepatic
cholangiocarcinoma
Phase I/II CQ + Metformin
Glioblastoma Phase I CQ + chemoradiation w
Brain metastasis Not provided CQ + radiotherapy
Adult solid neoplasm Phase I HCQ + Sunitinib Malate
Multiple myeloma Phase II CQ + Velcade (protease
Relapsed solid tumors Phase I HCQ + Sorafenib (RTKi
Advanced solid tumors Phase I HCQ + MK2206 (Akt in
Solid tumors Phase I CQ + carboplatin/gemc
Advanced cancers Phase I HCQ + vorinostat (HDA
HCQ + Sirolimus (mTO
Solid tumor Phase I HCQ + vorinostat (HDA
Adult solid tumor Phase I HCQ + temsirolimuscommonly used cancer therapies including a wide array of different
drugs and radiation (Thorburn et al., 2014; Rebecca and Amaravadi,
2015). Such studies are the basis for most of the current efforts to target
autophagy in patients (Table 2). Perhaps even more important than
chemo-sensitization, autophagy inhibition may overcome acquired re-
sistance to other anti-cancer agents. The best evidence for this is in tu-
mors with activating mutations in BRAF that have become resistant to
BRAF inhibitors like vemurafenib. Vemurafenib resistance in melanoma
is associatedwith increased autophagy and autophagy inhibition can re-
verse resistance associated with endoplasmic reticulum stress (Ma et
al., 2014). There is also evidence that autophagy inhibition to overcome
drug resistance can be effective in patients. A brain cancer patientwith a
BRAFmutant tumor that had become resistant to vemurafenib was suc-
cessfully treated with a combination of CQ and vemurafenib experienc-
ing long term tumor regression on the combination treatment (Levy et
al., 2014). Importantly, this patient had periods of time when the au-
tophagy inhibitor CQ was maintained but the BRAF inhibitor was
discontinued for periods of time. In every instance, this led to increased
tumor growth that was reversed when the combination treatment was
re-established. This case study is the ﬁrst to suggest that autophagy in-
hibition with CQ can overcome acquired resistance to the kinase inhib-
itor but that only combination treatment with both the BRAF inhibitor
and the autophagy inhibitor is effective. Continued follow up of this pa-
tient has demonstrated sustained tumor regression for over two and a
half years and more recent studies submitted for publication from
Mulcahy-Levy et al. have extended these ﬁndings to two other patients
both of whom acquired resistance to vemurafenib following successful
therapy and then experienced clinical improvement on the combination
of CQ and vemurafenib.
Althoughmost current clinical trials (Table 2) involve autophagy in-
hibition, there are arguments against this idea often revolving aroundatment of cancer.
Reference
ule inhibitors) NCT01446016
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NCT01023477
NCT01777477
NCT01506973
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ating) + 5-FU (DNA damaging) + Bevacizumab (angiogenesis NCT01206530
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ith temezolomide (alkylating agent) NCT02432417
NCT02496741
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NCT01727531
(RTKi) NCT00813423
inhibitor) + Cyclophosphamide (alkylating agent) NCT01438177
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(Zhong et al., 2016). It has been reported that “immunogenic” tumor
cell killing– i.e. killing cancer cells with chemotherapy in a way that
will lead to effective engagement of an anti-tumor immune response
– requires that the dying cancer cells have functional autophagy
(Michaud et al., 2011) leading to suggestions that we should try to en-
hance autophagy to improve cancer immunotherapy (Zhong et al.,
2016). Consistent with this idea, a recent study concluded that caloric
restriction could enhance tumor immunosurveillance only for autopha-
gy-proﬁcient tumors (Pietrocola et al., 2016). However, autophagy inhi-
bition can enhance immune cell-mediated, anti-tumor effects under at
least some circumstances (Liang et al., 2012; Baginska et al., 2013).
More work is needed to better understand the interplay between
autophagy's role(s) in the anti-tumor immune response.5. Clinical Trials of Targeted Autophagy Inhibition
Despite the caveats discussed above, there are already many studies
attempting to inhibit autophagy in cancer therapy. All the current stud-
ies use CQ or HCQ. These drugs inhibit the lysosome and block autoph-
agy while causing accumulation of autophagosomes and LC3, which
have been used as pharmacodynamicmarkers of the inhibitor's activity.
CQ and HCQ are inexpensive, approved drugs that have been used for
decades to treat malaria and arthritis but have some caveats as autoph-
agy inhibitors. First, they can have anti-tumor effects through other
mechanisms such as reducing nutrient scavenging and can sensitize to
other chemotherapies by autophagy-independent mechanisms (Eng
et al., 2016; Maycotte et al., 2012). Second, alterations in tumor pH
may affect drug bioavailability (Pellegrini et al., 2014).
Clinical trials targeting multiple neoplasms have been launched to
assess the effects of autophagy inhibition in combinationwith radiation,
conventional cytotoxic chemotherapies and targeted agents including
DNA damaging agents, HDAC inhibitors, proteasome inhibitors, mitotic
inhibitors, antiandrogens, and several kinase inhibitors (ClinicalTrials.
gov, Table 2). Additional studies inmelanoma, glioblastoma, pancreatic,
breast, lung, and prostate cancer are testing CQ/HCQ as a single agent
(ClinicalTrials.gov). A major caveat with the current clinical trials is
that we have no way to identify patients who are most likely to beneﬁt.
At least initially, one strategy to do this may be to focus on tumors with
mutations that confer sensitivity to autophagy inhibitors like the BRAF
mutant brain tumor studies mentioned above (Levy et al., 2014).
The ﬁrst Phase I and I/II trials have been reported testing autophagy
inhibition alone or in combination with a proteosome inhibitor
(bortezomib), radiation therapy, DNA damaging agents, i.e.
temazolomide and doxorubicin, as well as the mTOR inhibitor,
temsirolimus, and the HDAC inhibitor vorinostat (Rosenfeld et al.,
2014; Rangwala et al., 2014b; Rangwala et al., 2014a; Barnard et al.,
2014; Mahalingam et al., 2014; Vogl et al., 2014; Wolpin et al., 2014;
Rojas-Puentes et al., 2013; Patel et al., 2016). Doses effective for autoph-
agy inhibition can be reached with minimal side effects, although one
study in glioblastoma patients did report grade 3 and 4 neutropenia
and thrombopenia (Rosenfeld et al., 2014). Thus far, no studies have re-
ported adverse side effects expected of autophagy inhibition based on
pre-clinical animal studies, such as increased incidence of neuropathy,
secondary cancers, infections, ormetabolic disturbances. Encouragingly,
some studies suggest favorable clinical responses. Rangwala et al. re-
ported a partial response and stable disease in 14% and 27%, respective-
ly, of metastatic melanoma patients treated with HCQ in combination
with temozolomide, with a complete response and prolonged stable
disease seen in 2/6 patients with WT BRAF refractory melanoma
(Rangwala et al., 2014b). Moreover, a phase II study of CQ and radiation
therapy on brain metastasis in patients with advanced solid tumors re-
port progress free survival after one year in 84% of patients as compared
to 55% of patients in the control arm (radiation therapy alone) (Rojas-
Puentes et al., 2013).6. Outstanding Questions
In this articlewehave focused on just two types of disease (neurode-
generative disease and cancer)where different approaches to therapeu-
tically manipulate autophagy have been adopted and where clinical
studies are underway. However there are still many outstanding ques-
tions even for just these two areas. For example, although there is con-
siderable evidence that autophagy inhibition can make other anti-
cancer drugs more effective, this may only apply in tumor cells that
start off being dependent on autophagy. Indeed, in cancer cells that
are not autophagy-dependent the same drug combination may be an-
tagonistic rather than synergistic (Levy et al., 2014; Maycotte et al.,
2014); we are currently unable to predict if cancer cells will or won't
be autophagy-dependent. Some drugs are also thought to require au-
tophagy in order to kill cancer cells (Thorburn et al., 2014). In neurode-
generative diseases it is unclear whether or not different ways of
activating autophagy will be more or less effective and we are greatly
hampered by the fact that even for laboratory studies we lack good
tools to speciﬁcally activate autophagy without affecting other cellular
processes. In cancer therapy we have poor understanding of when au-
tophagy will increase tumor cell killing and when it will decrease it
and we need to better understand the interplay between autophagy
and the immune response to cancer. For any therapy involving autoph-
agy manipulation, a major problem is our inability to accurately mea-
sure autophagic ﬂux in vivo to assess if the intervention actually
worked.
Given the competing roles described above, an important question is
whether treatment of cancer by autophagy inhibitionwill lead to neuro-
degenerative side effects and likewise, that treatment of neurodegener-
ative diseases with autophagy promoting agents might promote pre-
malignant tumors. There are currently no studies that speciﬁcally in-
duce autophagy, making it difﬁcult to address the risk of autophagy in-
ducing agents. However, because activities like exercise and caloric
restriction that induce autophagy systemically (He et al., 2012;
Pietrocola et al., 2016) are known for their health advantages, we spec-
ulate that speciﬁc autophagy induction may be safe. Wemust also con-
sider the role of autophagy manipulation intended to treat one disease
on other systems and organs, such as the liver (Madrigal-Matute and
Cuervo, 2016).
7. Concluding Remarks
A danger is that if clinical studies of therapeutic targeting of autoph-
agy are ineffective, it may be because of our lack of knowledge about
who to treat and how best to manipulate autophagy and not because
autophagy manipulation is an ineffective therapy. It would be a pity if
autophagy-targeted therapies were abandoned when the problem
was that we didn't fully understand their effects rather than that au-
tophagy manipulation was never going to be effective. As with many
areas of biologywhere competing effects are seen– e.g. the immune sys-
tem can both promote and inhibit tumorigenesis while affecting a mul-
titude of other diseases, the key to successful implementation of
therapies designed to target a speciﬁc process lies in understanding
the biology and trying to speciﬁcally target the processes you want to
enhance or inhibit. Continued progress on understanding how autoph-
agy affects diseases like cancer andneurodegeneration and the develop-
ment of better ways to manipulate andmeasure these processes should
hopefully allow us to maximize the potential for autophagy manipula-
tion to treat disease.
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